Axsome Therapeutics(NASDAQ) AXSM

Market Cap$11.37B

Since IPO (2015)+2,427%

5 Year+823%

1 Year+111%

1 Month-6%

$219.76

-0.51%

-1.13Today

Axsome Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 220.89	2026-08-10

Axsome Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+4.67%	USD 211.04	2026-08-03
1 month	-5.52%	USD 233.80	2026-07-10
3 month	-1.4%	USD 224.03	2026-05-12
Year to date	+20.94%	USD 182.64	2025-12-31
1 year	+110.77%	USD 104.80	2025-08-08
3 year	+217.37%	USD 69.60	2023-08-11
5 year	+823.07%	USD 23.93	2021-08-11
Since inception	+2,427.35%	USD 8.74	2015-11-19

Axsome Therapeutics Financials at a Glance

Market Cap

$11.37B

Revenue (TTM)

$776.57M

Net Income (TTM)

-$191.64M

EPS (TTM)

-$3.74

P/E Ratio

-59.07

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$219.76

Volume

163,517.827

Open

$222.33

Price

$219.76

Volume

163,517.827

Open

$222.33

Previous Close

$220.89

Daily Range

$217.56 - $223.05

52-Week Range

$103.40 - $260.19

Estimated Earnings Date

Aug 10, 2026

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$219.76

Volume

163,517.827

Open

$222.33

Previous Close

$220.89

Daily Range

$217.56 - $223.05

52-Week Range

$103.40 - $260.19

Estimated Earnings Date

Aug 10, 2026

AXSM News

Page 1

AXSM: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Axsome Therapeutics

Axsome helps people with brain and nerve conditions feel better. They make medicines for depression, sleep disorders, and migraines. Their goal is to fill gaps in care with new types of treatments.

The Medicine Cabinet

AUVELITY: First oral medicine for adults with major depressive disorder that works on a specific brain receptor called NMDA; approved in August 2022.
SUNOSI: Daily pill used to treat excessive sleepiness in adults with sleep apnea or narcolepsy; acquired in 2022.
SYMBRAVO: Fast-acting oral treatment for adults experiencing migraine attacks; launched in the U.S. in June 2025.
Pipeline Candidates: Investigational drugs in clinical trials for Alzheimer's agitation, smoking cessation, ADHD, and fibromyalgia.

New Deals and Drugs

Acquired Jazz Pharmaceuticals' rights to SUNOSI in 2022 to enter the sleep medicine market.
Entered a 2020 license agreement with Pfizer to develop new treatments for narcolepsy and fibromyalgia.
Agreed to acquire global rights to AXS-17 from AstraZeneca in November 2025 to study its effects on epilepsy.
Purchased rights for a stabilized form of bupropion from DeuteRx in December 2025 to expand their research options.

What Makes Axsome Different

Axsome uses proprietary chemistry to make drugs dissolve faster and last longer in the bloodstream. They manage their own sales team in the United States while partnering with international companies to reach patients in Europe and the Middle East.

A Look at the Numbers

Total revenue reached $638.5 million in 2025, up 66% from the previous year.
Gross profit grew to $183.7 million in Q4 2025, a 69.7% increase compared to Q4 2024.
Net losses narrowed to $28.6 million in Q4 2025, an improvement of 61.9% from the same period in 2024.
The company had 712 full-time employees and a market cap of $9.5 billion as of late 2025.

The Evolution of Axsome

Axsome has transitioned from a research-focused startup to a commercial drug company with three approved products. Their strategy focuses on acquiring and developing unique chemical formulas to address underserved mental health and neurological needs.

AI Generated • Apr 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1,220

CEO

Herriott Tabuteau, MD

Website

www.axsome.com

Headquarters

New York City, NY 10007, US

AXSM Financials

Key Financial Metrics (TTM)

Gross Margin

93.24%

Operating Margin

-24.28%

Net Income Margin

-24.68%

Return on Equity

-255.60%

Return on Capital

-51.35%

Return on Assets

-25.17%

Earnings Yield

-1.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.37B

Shares Outstanding

51.46M

Volume

163.52K

Avg. Volume

860.18K

Financials (TTM)

Gross Profit

$724.04M

Operating Income

-$188.54M

EBITDA

-$179.79M

Operating Cash Flow

-$71.26M

Capital Expenditure

-$129.00K

Free Cash Flow

-$71.39M

Cash & ST Invst.

$319.85M

Total Debt

$219.21M

Axsome Therapeutics Performance Analysis

Axsome Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 50,037,106	N/A
2023	2023-12-31	USD 270,600,000	440.8%
2024	2024-12-31	USD 385,693,000	42.5%
2025	2025-12-31	USD 638,496,000	65.5%

Axsome Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	14.0%
Q4	2025-12-31	14.6%
Q1	2026-03-31	-2.4%
Q2	2026-06-30	14.2%

Axsome Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -4.60	32.8%
2023	2023-12-31	USD -5.27	14.4%
2024	2024-12-31	USD -5.99	13.8%
2025	2025-12-31	USD -3.68	-38.6%

Axsome Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	3.1%
Q4	2025-12-31	40.4%
Q1	2026-03-31	-125.0%
Q2	2026-06-30	21.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$218.38M

+45.5%

Gross Profit

$204.81M

+49.9%

Gross Margin

93.79%

N/A

Market Cap

$11.37B

N/A

Market Cap/Employee

$9.32M

N/A

Employees

1,220

N/A

Net Income

-$51.31M

-7.0%

EBITDA

-$49.65M

-16.6%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$319.85M

+5.6%

Total Debt

$219.21M

+0.9%

Accounts Receivable

$277.46M

+39.5%

Inventory

$37.88M

+105.4%

Long Term Debt

$148.56M

+2.5%

Short Term Debt

$70.65M

-2.4%

Return on Assets

-25.17%

N/A

Return on Invested Capital

-62.64%

N/A

Free Cash Flow

-$32.83M

-1.2%

Operating Cash Flow

-$32.95M

-1.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ARWRArrowhead Pharmaceuticals, Inc.

ARWRArrowhead Pharmaceuticals, Inc.$90.05+1.95%

CYTKCytokinetics, Incorporated

CYTKCytokinetics, Incorporated$77.44-0.06%

ABVXAbivax S.A.

ABVXAbivax S.A.$127.80+0.24%

NUVLNuvalent, Inc.

NUVLNuvalent, Inc.$123.96+0.00%

PCVXVaxcyte, Inc.

PCVXVaxcyte, Inc.$59.38+1.87%

RYTMRhythm Pharmaceuticals, Inc.

RYTMRhythm Pharmaceuticals, Inc.$115.33-0.13%

MTSRMetsera, Inc.

MTSRMetsera, Inc.$70.50-0.35%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$97.54+0.00%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$134.73-0.03%

RIOTRiot Platforms

RIOTRiot Platforms$20.15+0.04%

ACHRArcher Aviation

ACHRArcher Aviation$6.76+0.08%

WXMWf International

WXMWf International$8.02+1.00%

NVDANvidia

NVDANvidia$220.31+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.40+0.02%

Questions About AXSM

What is the current price of Axsome Therapeutics?

Axsome Therapeutics is trading at $217.86 per share.

What is the 52-week range for Axsome Therapeutics?

Over the past 52 weeks, Axsome Therapeutics has traded between $103.40 and $260.19.

How much debt does Axsome Therapeutics have?

As of the most recent reporting period, Axsome Therapeutics reported total debt of $219.90M.

How much cash does Axsome Therapeutics have on hand?

Axsome Therapeutics reported $305.11M in cash and cash equivalents in its most recent financial results.

What is Axsome Therapeutics’s dividend yield?

Axsome Therapeutics does not currently have a dividend yield.

Axsome Therapeutics(NASDAQ) AXSM

Axsome Therapeutics Financials at a Glance

AXSM News

Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does

5 Best Biotech Stocks for 2026 and How to Invest

3 Under-the-Radar Stocks to Buy and Hold

Better Growth Buy: Axsome vs Revolution Medicines

Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.

3 Stocks Poised to Disrupt the Healthcare Market by 2030

3 Overlooked Stocks Set to Soar in 2026

Why Did Axsome Therapeutics Stock Hit Another Record High Today?

AXSM: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Axsome Therapeutics

The Medicine Cabinet

New Deals and Drugs

What Makes Axsome Different

A Look at the Numbers

The Evolution of Axsome

AXSM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Axsome Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AXSM

What is the current price of Axsome Therapeutics?

What is the 52-week range for Axsome Therapeutics?

How much debt does Axsome Therapeutics have?

How much cash does Axsome Therapeutics have on hand?

What is Axsome Therapeutics’s dividend yield?

Premium Investing Services